Emerging Clinical Applications for Psychedelic Therapy

2 CE Hours available (APA approved)

Date: Sept. 6th, 2024
Time: 3 p.m. – 5 p.m.

Member: $78
Nonmember: $120*

Limited Time New Member Course Discount of 50%: If you sign up as a new member today ($155 Full Membership for first year), you’ll receive a discount code to register for the course for only $39.

Webinar Description

In this presentation, Dr. Barnett will describe various psychedelic compounds, their known mechanisms of action, and various subjective effects. He will review the past and current literature on the potential therapeutic benefits, as well as the risks, of psychedelic medicines on a variety of clinical conditions. Finally, he will discuss “trends and issues” in the broader psychedelic medicine field with a look at future directions. Discussion may also include psychedelic experiences outside of Western medical and research models, such as personal use, indigenous traditions, and religious use.

Objectives

1. List the names and differential subjective and physiological effects of at least four psychedelic substances.

2. Explain the basic pharmacological action of at least 3 psychedelic medicines.

3. Compare the potential risks and benefits of psychedelic experiences.

4. Describe at least 4 clinical conditions shown to be improved by at least two psychedelic compounds.

About the Speaker

Dr. Rick Barnett, Psy.D.  

Dr. Rick Barnett, Psy.D., is a licensed clinical psychologist and a licensed alcohol and drug counselor with an MS in Clinical Psychopharmacology. He operates a private group practice specializing in adults, older adults, and state-mandated patients with alcohol and other drug use disorders.

Dr. Barnett has served as President of APA Division 55 in 2020 and President of the Vermont Psychological Association from 2011 to 2014. He is currently the Chair of the Legislative Committee, focusing on Prescriptive Authority in Vermont.

In 2021, he co-founded the Psychedelic Society of Vermont after completing a yearlong training in psychedelic psychotherapy and research through the California Institute for Integral Studies (CIIS). Additionally, he is the Founder and CEO of CARTER, Inc., a 501(c)(3) nonprofit organization dedicated to the art and science of achieving lifelong freedom from addictive disorders.

Dr. Barnett was recently appointed Chair of the Psychedelic Therapy Advisory Group, as established by Act 126 in Vermont in 2024